Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 12:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 16,119 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorder Clear all
Completed Phase 2 Interventional

Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)

NCT05143190
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
PTR-01
Drug
Lead sponsor
Phoenix Tissue Repair, Inc.
Industry
Eligibility
12 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Redwood City, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Oct 28, 2026, 12:03 PM EDT
Completed Not applicable Interventional

Acupuncture for Aromatase Inhibitor Induced Joint Pain

NCT00826397
View directory record Official record
Conditions
Breast Cancer
Interventions
Acupuncture, Sham Acupuncture
Procedure
Lead sponsor
Columbia University
Other
Eligibility
45 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 28, 2026, 12:03 PM EDT
Completed Not applicable Interventional Results available

Ultrasound Efficacy in Moderate Rheumatoid Arthritis

NCT04662359
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Ultrasound Assessment
Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 28, 2026, 12:03 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer

NCT07374796
View directory record Official record
Conditions
Breast Cancer (Locally Advanced or Metastatic), Healthy Volunteers (HV), Unhealthy Volunteers, Breast Cancer Screening
Interventions
Epigenetic Assay
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2033
U.S. locations
1
States / cities
Glen Burnie, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 28, 2026, 12:03 PM EDT
Completed No phase listed Observational

Extended Follow-up of Columbia, MO Serum Bank Participants

NCT00340210
View directory record Official record
Conditions
Breast Cancer, Endometrial Cancer, Ovarian Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Female only
Enrollment
6,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 28, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy

NCT01449279
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 28, 2026, 12:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy

NCT01313117
View directory record Official record
Conditions
Peripheral Neuropathy
Interventions
Alpha lipoic acid
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 28, 2026, 12:03 PM EDT
Completed No phase listed Observational

Cardiotoxicity in Breast Cancer Patients Treated With Proton or Photon Radiotherapy: A RadComp Companion Study

NCT04361240
View directory record Official record
Conditions
Breast Cancer, Cardiotoxicity
Interventions
Proton vs Photon Radiation
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Warrenville, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 28, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss

NCT01325350
View directory record Official record
Conditions
Alopecia, Baldness
Interventions
bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C, bimatoprost vehicle solution, minoxidil 2% solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 59 Years · Female only
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Oct 28, 2026, 12:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

NCT02111850
View directory record Official record
Conditions
Cervical Cancer, Renal Cancer, Urothelial Cancer, Melanoma, Breast Cancer
Interventions
Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL), Cyclophosphamide, Fludarabine, Aldesleukin
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 28, 2026, 12:03 PM EDT
Completed No phase listed Observational

Investigation of Diagnostic Improvement Gained Through Optimization of MR Methods for Breast Cancer Detection

NCT02411760
View directory record Official record
Conditions
Breast Neoplasms
Interventions
3 Tesla Magnetic Resonance Imaging
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 28, 2026, 12:03 PM EDT
Not listed Phase 1 Interventional

Open-Label Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

NCT03415282
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RVT-501 0.5% topical ointment
Drug
Lead sponsor
Dermavant Sciences GmbH
Industry
Eligibility
2 Years to 11 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
12
States / cities
Anniston, Alabama • Irvine, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 28, 2026, 12:03 PM EDT
Recruiting Phase 2 Interventional

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

NCT07223424
View directory record Official record
Conditions
Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Colo-rectal Cancer (dMMR/MSI-H CRC), Hepatocellular Carcinoma, Ulcerative Colitis, Esophageal Cancer, Squamous Cell Carcinoma, Gastric/GEJ, Cervical Cancer, Gastro-Esophageal Adenocarcinoma, Esophageal Adenocarcinoma
Interventions
nivolumab, pembrolizumab
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 28, 2026, 12:03 PM EDT
Completed Phase 1 Interventional

Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream

NCT01853423
View directory record Official record
Conditions
Facial Angiofibroma
Interventions
Rapamune
Drug
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
3 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 28, 2026, 12:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

NCT06374459
View directory record Official record
Conditions
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Interventions
Zumsemetinib, Capecitabine, Zoledronic acid, Denosumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Westwood, Kansas • Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 12:03 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Open-Label Pilot Study of the Efficacy and Safety of Vusion Ointment for the Treatment of Intertrigo

NCT01118910
View directory record Official record
Conditions
Intertrigo
Interventions
Vusion
Drug
Lead sponsor
Image Dermatology P.C.
Other
Eligibility
12 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Montclair, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 4, 2011 · Synced Oct 28, 2026, 12:03 PM EDT
Terminated Not applicable Interventional

Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma

NCT01745224
View directory record Official record
Conditions
Melasma
Interventions
Revlite Q switched Nd:YAG, Trivantage Q switched Nd: YAG
Device
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 28, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

NCT03007979
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Cancer of Breast, Malignant Tumor of Breast
Interventions
Palbociclib, Letrozole, Fulvestrant, Optional research biopsy, Goserelin, Research blood draw, Circulating tumor cell blood draw, Tumor biopsy (optional)
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
St Louis, Missouri • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 28, 2026, 12:03 PM EDT
Terminated Not applicable Interventional

Insulin Differences Between African-American and Caucasian Female Adolescents With Polycystic Ovary Syndrome (PCOS)

NCT02052479
View directory record Official record
Conditions
Polycystic Ovary Syndrome, PCOS
Interventions
Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT)
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 28, 2026, 12:03 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers

NCT00613808
View directory record Official record
Conditions
Venous Ulcers
Interventions
Nitric Oxide 200ppm Group B
Drug
Lead sponsor
Nitric BioTherapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Denver, Colorado • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Oct 28, 2026, 12:03 PM EDT
Completed Phase 1Phase 2 Interventional

Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver

NCT00041808
View directory record Official record
Conditions
Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Breast Neoplasms, Melanoma, Sarcoma, Gastrointestinal Neoplasms, Lung Neoplasms, Liver Neoplasms, Cholangiocarcinoma
Interventions
MTC-DOX for Injection, Chemotherapy
Drug · Procedure
Lead sponsor
FeRx
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
3
States / cities
San Diego, California • San Francisco, California • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 28, 2026, 12:03 PM EDT
Completed No phase listed Observational

Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum

NCT00046189
View directory record Official record
Conditions
Xeroderma Pigmentosum, Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma, Skin Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Month to 99 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 28, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study

NCT00462423
View directory record Official record
Conditions
Metastatic Malignant Melanoma
Interventions
Avastin, Abraxane
Drug
Lead sponsor
Lynn E. Spitler, MD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
San Francisco, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Oct 28, 2026, 12:03 PM EDT
Completed Not applicable Interventional

Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer II)

NCT00929617
View directory record Official record
Conditions
Breast Cancer
Interventions
Experimental 1: exercise with 2 counseling types, Usual Care - written materials
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Birmingham, Alabama • Champaign, Illinois • Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 28, 2026, 12:03 PM EDT